Am J Transplant, Volume 5, Suppl 3 Archives - Page 57 of 170 - ATC Abstracts

2015 American Transplant Congress
Outcomes of Hepatitis C Virus (HCV) Treatment Following Liver Transplantation in the Era of Direct-Acting Antiviral Medications
S. Baggett,¹ D. Jones,¹ M. Shoreibah.²
¹Department of Pharmacy, UAB Hospital, Birmingham, AL; ²Department of Gastroenterology, UAB Hospital, Birmingham, AL.
BACKGROUND: The treatment of HCV is one of the most rapidly changing areas of medical practice. These agents have been shown to be safe and…
2015 American Transplant Congress
Pharmacist-Led Renal-Sparing Conversion to Everolimus After Liver Transplantation
T. Horwedel,¹ L. Bowman,¹ W. Chapman,² J. Hagopian.¹
¹Barnes-Jewish Hospital, St. Louis, MO; ²Washington University in St. Louis, St. Louis, MO.
Purpose: Preservation of renal function following orthotopic liver transplantation (OLT) through calcineurin inhibitor (CNI)-minimization is an established clinical objective. The use of everolimus (EVR) to…
2015 American Transplant Congress
Should We Ever Pay Living Kidney Donors? Focus Group Study of Public Opinion
A. Tong,^1,2 A. Ralph,^1,2 J. Chapman,³ G. Wong,^1,2,3 J. Gill,⁴ M. Josephson,⁵ C. Hanson,^1,2 J. Craig.^1,2
¹School of Public Health, The University of Sydney, Sydney, Australia; ²Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia; ³Centre for Transplant and Renal Research, Westmead Hospital, Sydney, Australia; ⁴Division of Nephrology, University of British Columbia, Vancouver, Canada; ⁵Department of Medicine, University of Chicago, Chicago.
Background: The unmet demand for kidney transplantation has generated intense controversy about introducing incentives for living kidney donors to increase donation rates. Such debates may…
2015 American Transplant Congress
PI3Kα and STAT1 Interplay Regulates Human Mesenchymal Stem Cell Immune Polarization
E. Kefalogianni,¹ M. Mounayar,² B. Smith,² J. Azzi,² L. Chabtini,² P. Fiorina,² M. Kraus,³ R. Briddell,⁴ W. Fodor,⁵ A. Herrlich,¹ R. Abdi.²
¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ²Transplantation Research Center, Brigham and Women's and Children's Hospital, Harvard Medical School, Boston, MA; ³Viacord LLC, a PerkinElmer Company, Cambridge, MA; ⁴ViaCord Processing Lab, Viacord LLC, a PerkinElmer Company, Hebron, KY; ⁵The Cell Therapy Group, Madison, CT.
The immunomodulatory capacity of mesenchymal stem cells (MSC) is critical for their use in therapeutic applications. MSC response to specific inflammatory cues allows them to…
2015 American Transplant Congress
HO-1 Modified Macrophages Promote Autophagy by Activating Sirt1/TGF-β/Smad4 Signaling in Ischemia-Stressed Mouse Liver Transplants
S. Yue, J. Huang, K. Nakamura, M. Zhou, X.-D. Shen, R. Busuttil, B. Ke, J. Kupiec-Weglinski.
Dumont-UCLA Transplant Ctr, Dept. of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Background: Although heme oxygenase-1 (HO-1) is known to induce alternative macrophage activation towards an anti-inflammatory M2 phenotype, the underlying mechanisms remain elusive. Autophagy may play…
2015 American Transplant Congress
Hybrid Ostomy – New Technique in Intestinal Transplantation
T. Beduschi, J. Garcia, P. Ruiz, A. Tekin, G. Selvaggi, S. Nishida, J. Fan, R. Vianna.
Miami Transplant Institute, University of Miami Miller School of Medicine, Miami, FL.
Introduction: Many experimental non-invasive methods have been tested to assess the intestinal graft, but none of them proved to be reliable. Biopsy of the intestine…
2015 American Transplant Congress
Impact of Anti-CMV Prophylactic Therapy on the Development of CMV Quantiferon Sero-Conversion in High-Risk Patients
A. Palanisamy, D. Taber, N. Pilch, C. Bratton, J. McGillicuddy, P. Baliga, K. Chavin.
Transplant Surgery, Medical University of South Carolina, Charleston, SC.
Body: Abdominal organ transplants at high risk for CMV infection (D+/R) remain a difficult cohort to prevent late CMV infection despite prolonged valganciclovir (VGC) administration.…
2015 American Transplant Congress
The Impact of Administrating Everolimus Before Cytomegalovirus Infection to Prevent CMV Recurrence in Heart Transplant Recipients
M. Ishida, K. Toda, T. Nakamura, S. Miyagawa, Y. Yoshikawa, S. Fukushima, S. Saito, D. Yoshioka, K. Kubota, T. Ueno, T. Kuratani, Y. Sawa.
Cardiovascular Surgery, Osaka University, Suita, Osaka, Japan.
Purpose – Cytomegalovirus (CMV) infection is a major complication in heart transplant recipients. Recent trials indicate that the use of the mammalian target of rapamycin…
2015 American Transplant Congress
Variability in Incidence of Clostridium difficile Infections and Associated Mortality Among Solid Organ Transplant Recipients
N. Piccicacco, C. Doligalski, A. Logan.
Pharmacy, Tampa General Hospital, Tampa, FL.
Purpose: Solid organ transplant (SOT) recipients are at risk for Clostridium difficile infection (CDI) due to immunosuppression, frequent healthcare system contact, and liberal use of…
2015 American Transplant Congress
Proteasome Inhibition by Bortezomib Prevents Early Graft Failure After Pancreatic Islet Transplantation
H. Ono,¹ Y. Asahi,¹ T. Yoshida,¹ Y. Koshizuka,¹ M. Watanabe,¹ U. Tomaru,² S. Emoto,¹ M. Fukai,³ A. Taketomi,¹ S. Todo,⁴ K. Yamashita.³
¹Gastroenterological Surgery1, Hokkaido University Graduate School of Medicine, Sapporo, Japan; ²Department of Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; ³Department of Transplant Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan; ⁴St Mary's Hospital, Kurume, Japan.
Background: Islet graft loss caused by injurious inflammatory and innate immune responses, is a major obstacle in pancreatic islet transplantation (PIT). In this pathophysiology, the…